FH and familial hyperaldosteronism: Although patients with markedly elevated LDL-C levels are more likely to be tested for founder mutations, majority of patients with probable FH were not studied for genetic mutations of FH as recommended in Current Care Guidelines and one third of the testing was directed to patients with lower pre-test probability (possible FH) when the decision for testing was based solely on clinicians’ awareness.